- Home
- CMBT vs IMCR Comparison
CMBT vs IMCR Comparison
Compare CMBT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBT
- IMCR
- Stock Information
- Founded
- CMBT 1989
- IMCR 2008
- Country
- CMBT Belgium
- IMCR United Kingdom
- Employees
- CMBT N/A
- IMCR N/A
- Industry
- CMBT
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMBT
- IMCR Health Care
- Exchange
- CMBT NYSE
- IMCR Nasdaq
- Market Cap
- CMBT 1.7B
- IMCR 1.5B
- IPO Year
- CMBT N/A
- IMCR 2021
- Fundamental
- Price
- CMBT $9.48
- IMCR $31.34
- Analyst Decision
- CMBT
- IMCR Buy
- Analyst Count
- CMBT 0
- IMCR 10
- Target Price
- CMBT N/A
- IMCR $58.13
- AVG Volume (30 Days)
- CMBT 120.3K
- IMCR 560.7K
- Earning Date
- CMBT 08-07-2025
- IMCR 08-07-2025
- Dividend Yield
- CMBT 12.11%
- IMCR N/A
- EPS Growth
- CMBT N/A
- IMCR N/A
- EPS
- CMBT 2.16
- IMCR N/A
- Revenue
- CMBT $934,913,000.00
- IMCR $333,581,000.00
- Revenue This Year
- CMBT $5.05
- IMCR $26.82
- Revenue Next Year
- CMBT $24.22
- IMCR $8.15
- P/E Ratio
- CMBT $4.45
- IMCR N/A
- Revenue Growth
- CMBT N/A
- IMCR 25.75
- 52 Week Low
- CMBT $7.65
- IMCR $23.15
- 52 Week High
- CMBT $18.43
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- CMBT 52.39
- IMCR 40.28
- Support Level
- CMBT $9.38
- IMCR $35.10
- Resistance Level
- CMBT $9.75
- IMCR $37.56
- Average True Range (ATR)
- CMBT 0.35
- IMCR 1.74
- MACD
- CMBT 0.01
- IMCR -0.79
- Stochastic Oscillator
- CMBT 61.48
- IMCR 0.75
About CMBT EURONAV
CMB.Tech NV owns and operates a fleet of vessels for international maritime shipping and storage of crude oil and petroleum products. It generate a large parts of their revenue from voyage charters, including vessels in pools that predominantly perform voyage charters. The company organizes itself into three divisons: the Marine division, the H2 Infra division and the H2 Industry division. The Marine Division derives maximum revenue.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.